<DOC>
	<DOCNO>NCT02327169</DOCNO>
	<brief_summary>The primary purpose study determine safety profile maximum tolerate dos ( MTDs/potential recommend phase 2 dos ( RP2Ds ) combination treatment MLN2480 + MLN0128 , MLN2480 + alisertib , MLN2480 + paclitaxel , MLN2480 + cetuximab , MLN2480 + irinotecan patient advance nonhematologic malignancy .</brief_summary>
	<brief_title>A Phase 1B Study MLN2480 Combination With MLN0128 Alisertib , Paclitaxel , Cetuximab , Irinotecan Adult Patients With Advanced Nonhematologic Malignancies</brief_title>
	<detailed_description>The drug test study call MLN2480 . MLN2480 test evaluate side effect determine maximum tolerate dose ( MTD ) recommend dose future study administer combination three medication . This study ass safety MLN2480 well process body participant solid nonhematologic malignancy fail standard therapy . The study conduct two phase , Dose Escalation Phase Dose Expansion Phase . Approximately 49 participatns enrol Escalation phase . Participants phase assign one five treatment group : - MLN2480 + MLN0128 - MLN2480 + Alisertib - MLN2480 + Paclitaxel - MLN2480 + Cetuximab - MLN2480 + Irinotecan Once MTD combination treatment arm establish Escalation Phase , one combination treatment select Expansion Phase . Approximately 76 participant enrolled Expansion Phase . This multi-centre trial conduct worldwide . The overall time participate study approximately 14 month . Participants make approximately 43 visit clinic include end study visit 30 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>All Treatment Arms : 1 . Informed consent . 2 . Male female participant 18 year old . 3 . Participants , opinion treat physician , fail standard therapy phase 1 trial appropriate option . 4 . Radiographically clinically evaluable tumor . For Expansion phase : Tumors must measurable protocol specify genetic mutational status , applicable . 5 . Recovered ( ie , ≤ Grade 1 toxicity ) adverse effect ( except alopecia ) prior therapy . 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 7 . Expected survival time least 3 month opinion investigator . 8 . Block bank tumor tissue and/or ≥ 10 unstained slide . Participants satisfy eligibility criterion bank tissue/slides may ask consent baseline biopsy . 9 . Suitable vein access studyrequired blood sampling . 10 . Thyroid function test consistent stable thyroid function . Note : Participants stable dose thyroid replacement therapy suggest minimum 12 week Cycle 1 , Day 1 eligible . 11 . Left ventricular ejection fraction ( LVEF ) 50 % great , measure echocardiogram ( ECHO ) multiplegated acquisition scan ( MUGA ) , within 28 day first dose MLN2480 12 . Female participant post menopausal least 1 year , surgically sterile , agree practice 2 effective method contraception 120 day ( 4 month ) last dose study drug participant Arms 1 , 2 , 5 , 6 month participant Arms 3 4 , agree practice true abstinence . 13 . Male patient , even surgically sterilize , agree practice effective barrier contraception 120 day ( 4 month ) last dose study drug participant Arms 1 , 2 , 5 , 6 month participant Arms 3 , 4 , agree practice true abstinence . 14 . Additional inclusion criterion Arm 3 Expansion Only ( MLN2480 + paclitaxel ) : . Participants KRAS exon 2 BRAF nonV600 mutationpositive non small cell lung cancer ( NSCLC ) receive minimum 1 2 prior cytotoxicapproved regimen . 15 . Additional inclusion criterion Arms 4 5 Expansion Only ( MLN2480 + cetuximab ; MLN2480 + irinotecan ) : 1 . Participants CRC receive minimum 1 2 prior cytotoxicapproved regimen . All treatment arm : 1 . Female participant pregnant currently breastfeed . 2 . History serious medical psychiatric illness could , investigator 's opinion , potentially interfere safe protocol completion . 3 . History uncontrolled brain metastasis unless : previously treat surgery , wholebrain radiation , stereotactic radiosurgery ; stable disease ≥ 60 day without steroid use ( stable steroid dose establish ≥ 28 day first dose MLN2480 ) . 4 . Ongoing seizure disorder requirement antieplieptics . 5 . Recent prior therapy , include : chemotherapy hormonal therapy ≤ 4 week 4 half life , whichever occur first , administration study drug ; immunotherapy/monoclonal antibody use ≤ 4 week administration MLN2480 ; radiation therapy ≤ 3 week administration study drug . 6 . Chronic therapeutic corticosteroid use exception replacement therapy adrenal insufficiency corticosteroid inhaler . 7 . Known history human immunodeficiency virus infection , hepatitis B , hepatitis C ; Prior allogeneic bone marrow organ transplantation , active condition chronic immune suppression allow . 8 . Concomitant use , administration ≤ 14 day first dose study drug ( ) , clinically significant enzyme inducer . 9 . Treatment gemfibrozil ( strong CYP2C8 inhibitor ) within 14 day first dose MLN2480 . 14 . History current illicit drug use , drug abuse , alcohol abuse . 10 . Major surgery within 14 day first dose study drug . 11 . Inability comply study requirement . 12 . Other unspecified reason , opinion investigator Millennium , make patient unsuitable enrollment . 13 . Expansion phase : Prior treatment RAF , MEK , inhibitor MAPK pathway . 14 . Additional exclusion criterion Arm 2 Only ( MLN2480 + alisertib ) : . History uncontrolled sleep apnea syndrome condition could result excessive daytime sleepiness , severe chronic obstructive pulmonary disease . 15 . Additional exclusion criterion Arm 3 Only ( MLN2480 + paclitaxel ) : . Known hypersensitivity paclitaxel component drug formulate Cremophor® EL ( polyoxyethylated castor oil ) . 16 . Additional exclusion criterion Arm 5 Only ( MLN2480 + irinotecan ) : 1 . Use strong moderate CYP3A inhibitor ≤ day first dose irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>